PE20001428A1 - Composicion de liberacion modificada - Google Patents
Composicion de liberacion modificadaInfo
- Publication number
- PE20001428A1 PE20001428A1 PE1999001147A PE00114799A PE20001428A1 PE 20001428 A1 PE20001428 A1 PE 20001428A1 PE 1999001147 A PE1999001147 A PE 1999001147A PE 00114799 A PE00114799 A PE 00114799A PE 20001428 A1 PE20001428 A1 PE 20001428A1
- Authority
- PE
- Peru
- Prior art keywords
- disgreased
- diona
- thiazolidin
- methacrylates
- benzyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN SENSIBILIZADOR DE INSULINA 5-[4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]BENCIL]TIAZOLIDIN-2,4-DIONA; 5-[4-[2-(5-ETILPIRIDIN-2-IL)ETOXI]BENCIL]TIAZOLIDIN-2,4-DIONA (PIOGLITAZONA); (+)-5-[[4-[(3,4-DIHIDRO-6-HIDROXI-2,5,7,8-TETRAMETIL-2H-1-BENZOPIRAN-2-IL)METOXI]-FENIL]METIL]-2,4-TIAZOLODINADIONA (TROGLITAZONA); VEHICULO FARMACEUTICAMENTE ACEPTABLE. LA COMPOSICION PUEDE SER DE LIBERACION RETARDADA, IMPULSADA; O ES UN COMPRIMIDO CON REVESTIMIENTO ENTERICO DE UNA O MULTIPLES CAPAS O EL COMPRIMIDO ESTA REVESTIDO CON UN POLIMERO RESISTENTE A ACIDOS GASTRICOS, SIENDO EL POLIMERO SELECCIONADO DE METACRILATOS, ACETATO F-TALATO DE CELULOSA, POLI(ACETATO FTALATO DE VINILO), FTALATO DE HIDROXIPROPILMETILCELULOSA, SI LA COMPOSICION ES DE LIBERACION SOSTENIDA PRESENTA UNA MATRIZ i)QUE NO SE DISGREGA POR LA INCORPORACION DE METACRILATOS, ACETATO DE CELULOSA, FTALATO DE HIDROXIPROPILMETILCELULOSA A LA MATRIZ; ii)QUE SE DISGREGA, iii)QUE SE EROSIONA; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9824870.1A GB9824870D0 (en) | 1998-11-12 | 1998-11-12 | Novel composition and use |
GBGB9912189.9A GB9912189D0 (en) | 1999-05-25 | 1999-05-25 | Novel composition and use |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20001428A1 true PE20001428A1 (es) | 2001-02-08 |
Family
ID=26314667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1999001147A PE20001428A1 (es) | 1998-11-12 | 1999-11-12 | Composicion de liberacion modificada |
Country Status (39)
Country | Link |
---|---|
EP (3) | EP1128827B1 (es) |
JP (1) | JP2002529505A (es) |
KR (2) | KR100732599B1 (es) |
CN (1) | CN1289081C (es) |
AP (2) | AP2008004490A0 (es) |
AR (2) | AR023700A1 (es) |
AT (1) | ATE382352T1 (es) |
AU (1) | AU768578B2 (es) |
BG (2) | BG109893A (es) |
BR (1) | BR9915215A (es) |
CA (1) | CA2350659C (es) |
CO (1) | CO5190673A1 (es) |
CY (1) | CY1107909T1 (es) |
CZ (1) | CZ20011628A3 (es) |
DE (1) | DE69937898T2 (es) |
DK (1) | DK1128827T3 (es) |
DZ (1) | DZ2937A1 (es) |
EA (3) | EA200601144A1 (es) |
EG (2) | EG24463A (es) |
ES (1) | ES2299269T3 (es) |
HK (1) | HK1040909B (es) |
HR (2) | HRP20010342B1 (es) |
HU (1) | HUP0104307A3 (es) |
ID (1) | ID29344A (es) |
IL (2) | IL143003A0 (es) |
MY (1) | MY135973A (es) |
NO (1) | NO20012351L (es) |
NZ (2) | NZ511611A (es) |
OA (1) | OA11676A (es) |
PE (1) | PE20001428A1 (es) |
PL (1) | PL198717B1 (es) |
PT (1) | PT1128827E (es) |
RS (1) | RS50208B (es) |
SI (1) | SI1128827T1 (es) |
SK (1) | SK286937B6 (es) |
TR (2) | TR200101337T2 (es) |
TW (2) | TWI257305B (es) |
UY (2) | UY25798A1 (es) |
WO (1) | WO2000028990A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
MY125516A (en) | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
JP2004504264A (ja) * | 2000-01-07 | 2004-02-12 | ユニバーシティ オブ シンシナティ | Th1又はth2リンパ球に制御される免疫応答の選択的活性化 |
WO2002060415A1 (de) * | 2001-01-31 | 2002-08-08 | Röhm GmbH & Co. KG | Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen |
JP2005514399A (ja) * | 2001-12-21 | 2005-05-19 | スミスクライン ビーチャム コーポレーション | PPARγアクチベーターの投薬法 |
MY139719A (en) * | 2002-02-12 | 2009-10-30 | Glaxo Group Ltd | Oral dosage form for controlled drug release |
EP1552832A1 (en) * | 2002-07-11 | 2005-07-13 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
US7018658B2 (en) * | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
EP1589951B1 (en) * | 2003-01-03 | 2017-08-09 | Supernus Pharmaceuticals, Inc. | Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics |
EP1588708A4 (en) | 2003-01-29 | 2006-03-01 | Takeda Pharmaceutical | METHOD FOR PRODUCING COATED PREPARATION |
ES2241478B1 (es) * | 2004-02-13 | 2006-11-16 | Lacer S.A. | Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo. |
FI20060501L (fi) * | 2006-05-22 | 2007-11-23 | Biohit Oyj | Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa |
CN103945832B (zh) * | 2011-07-14 | 2017-03-29 | 能脑有限责任公司 | 用于脑能量分子延迟释放和持续释放的组合物,装置及方法 |
CA2936748C (en) | 2014-10-31 | 2017-08-08 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5697277A (en) | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
US4582839A (en) | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
DK173350B1 (da) | 1985-02-26 | 2000-08-07 | Sankyo Co | Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem |
JPH06779B2 (ja) | 1985-06-10 | 1994-01-05 | 武田薬品工業株式会社 | チアゾリジオン誘導体およびそれを含んでなる医薬組成物 |
US4812570A (en) | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
ATE186724T1 (de) | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
US4791125A (en) | 1987-12-02 | 1988-12-13 | Pfizer Inc. | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents |
WO1989008650A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
MX15171A (es) | 1988-03-08 | 1993-05-01 | Pfizer | Derivados de tiazolidinodiona hipoglicemicos |
WO1991007107A1 (en) | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
EP0533933A4 (en) | 1990-07-03 | 1993-05-05 | Yamanouchi Pharmaceutical Co. Ltd. | Bisheterocyclic compound |
HUT70153A (en) | 1990-08-23 | 1995-09-28 | Pfizer | Hypoglycemic hydroxyurea derivatives |
JPH04210683A (ja) | 1990-12-06 | 1992-07-31 | Terumo Corp | チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬 |
CA2106967C (en) | 1991-04-11 | 2003-12-09 | Takashi Sohda | Thiazolidinedione derivatives, production and use thereof |
US5183823A (en) | 1991-04-11 | 1993-02-02 | Takeda Chemical Industries, Ltd. | Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents |
US5502078A (en) * | 1991-05-28 | 1996-03-26 | Zeneca Limited | Chemical compounds |
TW222626B (es) | 1991-07-22 | 1994-04-21 | Pfizer | |
FR2680512B1 (fr) | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
JPH05271204A (ja) | 1992-03-26 | 1993-10-19 | Japan Tobacco Inc | 新規なトリアジン誘導体 |
US5264451A (en) | 1992-04-07 | 1993-11-23 | American Home Products Corporation | Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones |
WO1993021166A1 (en) | 1992-04-10 | 1993-10-28 | Smithkline Beecham Plc | Heterocyclic compounds and their use in the treatment of type ii-diabetes |
AU4104593A (en) | 1992-05-05 | 1993-11-29 | Upjohn Company, The | A process for producing pioglitazone metabolite |
JPH07508747A (ja) | 1992-07-03 | 1995-09-28 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 医薬用複素環化合物 |
US5326770A (en) * | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
US5232945A (en) | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
GB9218830D0 (en) | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
US5457109A (en) | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
DE4432757A1 (de) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
US5952509A (en) * | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
JP3256841B2 (ja) * | 1996-06-27 | 2002-02-18 | 武田薬品工業株式会社 | ベンズアルデヒド化合物の製造法 |
GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
IL132032A0 (en) * | 1997-03-24 | 2001-03-19 | Galderma Res & Dev | Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus |
-
1999
- 1999-11-10 AR ARP990105699A patent/AR023700A1/es unknown
- 1999-11-10 AR ARP990105698A patent/AR023699A1/es unknown
- 1999-11-10 DZ DZ990237A patent/DZ2937A1/xx active
- 1999-11-11 MY MYPI99004894A patent/MY135973A/en unknown
- 1999-11-11 EG EG142999A patent/EG24463A/xx active
- 1999-11-11 EG EG142899A patent/EG22344A/xx active
- 1999-11-11 CO CO99070989A patent/CO5190673A1/es not_active Application Discontinuation
- 1999-11-12 PT PT99956029T patent/PT1128827E/pt unknown
- 1999-11-12 KR KR1020017005949A patent/KR100732599B1/ko not_active IP Right Cessation
- 1999-11-12 HU HU0104307A patent/HUP0104307A3/hu unknown
- 1999-11-12 IL IL14300399A patent/IL143003A0/xx unknown
- 1999-11-12 ID IDW00200101047A patent/ID29344A/id unknown
- 1999-11-12 NZ NZ511611A patent/NZ511611A/en not_active IP Right Cessation
- 1999-11-12 EP EP99956029A patent/EP1128827B1/en not_active Expired - Lifetime
- 1999-11-12 JP JP2000582037A patent/JP2002529505A/ja active Pending
- 1999-11-12 SK SK643-2001A patent/SK286937B6/sk not_active IP Right Cessation
- 1999-11-12 EA EA200601144A patent/EA200601144A1/ru unknown
- 1999-11-12 RS YU36401A patent/RS50208B/sr unknown
- 1999-11-12 EP EP07150269A patent/EP1917962A1/en not_active Withdrawn
- 1999-11-12 PL PL348153A patent/PL198717B1/pl not_active IP Right Cessation
- 1999-11-12 EP EP07105991A patent/EP1815855A1/en not_active Withdrawn
- 1999-11-12 EA EA200702648A patent/EA200702648A1/ru unknown
- 1999-11-12 PE PE1999001147A patent/PE20001428A1/es not_active Application Discontinuation
- 1999-11-12 KR KR1020067017464A patent/KR20060097140A/ko not_active Application Discontinuation
- 1999-11-12 CZ CZ20011628A patent/CZ20011628A3/cs unknown
- 1999-11-12 CN CNB998154946A patent/CN1289081C/zh not_active Expired - Fee Related
- 1999-11-12 AP AP2008004490A patent/AP2008004490A0/xx unknown
- 1999-11-12 CA CA002350659A patent/CA2350659C/en not_active Expired - Fee Related
- 1999-11-12 DK DK99956029T patent/DK1128827T3/da active
- 1999-11-12 EA EA200100540A patent/EA007608B1/ru not_active IP Right Cessation
- 1999-11-12 UY UY25798A patent/UY25798A1/es not_active Application Discontinuation
- 1999-11-12 OA OA1200100116A patent/OA11676A/en unknown
- 1999-11-12 WO PCT/EP1999/009031 patent/WO2000028990A1/en active Application Filing
- 1999-11-12 AU AU12729/00A patent/AU768578B2/en not_active Ceased
- 1999-11-12 TR TR2001/01337T patent/TR200101337T2/xx unknown
- 1999-11-12 TR TR2005/03846T patent/TR200503846T2/xx unknown
- 1999-11-12 AT AT99956029T patent/ATE382352T1/de not_active IP Right Cessation
- 1999-11-12 AP APAP/P/2001/002135A patent/AP1901A/en active
- 1999-11-12 DE DE69937898T patent/DE69937898T2/de not_active Expired - Lifetime
- 1999-11-12 NZ NZ526440A patent/NZ526440A/en not_active IP Right Cessation
- 1999-11-12 BR BR9915215-0A patent/BR9915215A/pt not_active Application Discontinuation
- 1999-11-12 SI SI9931001T patent/SI1128827T1/sl unknown
- 1999-11-12 ES ES99956029T patent/ES2299269T3/es not_active Expired - Lifetime
- 1999-11-15 UY UY25800A patent/UY25800A1/es not_active Application Discontinuation
- 1999-12-24 TW TW093132308A patent/TWI257305B/zh active
- 1999-12-24 TW TW088122852A patent/TWI246920B/zh not_active IP Right Cessation
-
2001
- 2001-05-11 NO NO20012351A patent/NO20012351L/no not_active Application Discontinuation
- 2001-05-11 HR HR20010342A patent/HRP20010342B1/xx not_active IP Right Cessation
- 2001-06-07 BG BG109893A patent/BG109893A/bg unknown
- 2001-06-07 BG BG105570A patent/BG65444B1/bg unknown
-
2002
- 2002-02-08 HK HK02101021.9A patent/HK1040909B/zh not_active IP Right Cessation
-
2007
- 2007-06-14 IL IL183972A patent/IL183972A0/en unknown
-
2008
- 2008-03-17 HR HR20080117A patent/HRP20080117A2/xx not_active Application Discontinuation
- 2008-03-19 CY CY20081100310T patent/CY1107909T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20001428A1 (es) | Composicion de liberacion modificada | |
EA200601145A1 (ru) | Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов | |
UY25049A1 (es) | Composiciones para tratamiento para diabetes mellitus | |
EA200000970A1 (ru) | Фармацевтическая лекарственная форма, включающая 2-[[(2-пиридинил) метил]сульфинил] бензимидазол, обладающий противоязвенной активностью, и способ изготовления такой лекарственной формы | |
BRPI0606768A2 (pt) | forma de dosagem oral compreendendo rosiglitazona | |
TW200700063A (en) | Oral dosage form comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | |
EP1078923A3 (en) | Process for the preparation of benzothiophene derivatives | |
AR015894A1 (es) | Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos | |
CO4940420A1 (es) | Nuevo metodo de tratamiento | |
AR015120A1 (es) | Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica | |
CY1105354T1 (el) | Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο | |
CO4940489A1 (es) | Nuevo metodo de tratamiento cines asociadas a la misma en mamiferos | |
PE20050335A1 (es) | Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion | |
AR038417A1 (es) | Forma de dosificacion oral, procedimiento para prepararla y uso de una base debil farmaceuticamente aceptable o una sal o solvato farmaceuticamente aceptable de la misma para preparar dicha forma de dosificacion oral | |
NZ515555A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
CY1107252T1 (el) | Τρυγικο αλας παραγωγου της θειζολιδινοδιονης | |
UY25051A1 (es) | Composiciones para el tratamiento de diabetes mellitus | |
AU2002343052A1 (en) | Rosiglitazone edisylates and their use as antidiabetics | |
PE20001239A1 (es) | Composicion de un sensibilizador de insulina | |
MXPA02012100A (es) | Sal de tiazodilindiona para el tratamiento de la diabetes mellitus. | |
CY1107767T1 (el) | Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο | |
WO2003099337A3 (en) | Inclusion complexes of rosiglitazone | |
AR018994A1 (es) | Compuestos tiazolidindiona, un proceso para su preparacion, composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento | |
AP2002002684A0 (en) | 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical | |
CO5150180A1 (es) | Nueva composicion y uso liberacion modificada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |